Manuscript on use of 89Zr pembrolizumab in NHPs

An ARRIVE-compliant manuscript submitted for open-access publication describing 89Zr-pembrolizuab in NHPResponsible: MSDVerification: (1) Minutes of WP4 meeting including prospective sample size calculation and prospective protocol; (2) Opinion of TRISTAN’s independent Ethics Advisory Board that use of NHP is justified in the context of the entire project goals; (3) PDF of manuscript; (4) Email from journal acknowledging receipt of manuscript; (4) A copy of the page on the TRISTAN data inventory (5.0.D1) which shows a record for the data acquired in order to generate this deliverable; (5) url of the site (5.0.D4) containing any SOPs and any exemplar data-sets associated with this deliverable.GNG 4.3.G3: In vivo experiments in NHP justify a clinical studyVerification: Minutes of WP4 meetingConsequence: Non-human primate study will not be performedDate: M29